# US 2006/0076011 A1 · Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0076011 A1
- Document ID: US20060076011A1
- Status: Published application
- Kind: A1
- Application number: 11/192,852
- Filed: 2005-07-29
- Published: 2006-04-13
- Earliest claimed: 1999-11-08
- Assignees: Capnia, Inc.
- Inventors: Julia Rasor; Ned Rasor; Gerard Pereira
- Web page: https://patentgrep.com/patent/US20060076011A1

## CPC

- A61K 47/02: Inorganic compounds
- A61M 15/0003: {with means for dispensing more than one drug}
- A61H 33/14: Devices for gas baths with ozone, hydrogen, or the like (production of ozone or hydrogen C01B, C25B1/02)
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/21: Esters, e.g. nitroglycerine, selenocyanates
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/46: 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 38/085: {Angiotensins}
- A61M 11/06: of the injector type
- A61M 13/00: Insufflators for therapeutic or disinfectant purposes {, i.e. devices for blowing a gas, powder or vapour into the body (hand-held units in which gas flow is produced by muscular energy at the moment of use B05B11/062)}
- A61M 15/0041: {with movable piercing or cutting means}
- A61M 15/0081: {Locking means}
- A61M 15/009: {using medicine packages with incorporated spraying means, e.g. aerosol cans (pocket atomiser of the injector type A61M11/08)}
- A61M 37/00: Other apparatus for introducing media into the body (for reproduction or fertilisation A61B17/425; apparatus for iontophoresis or cataphoresis A61N1/30); Percutany, i.e. introducing medicines into the body by diffusion through the skin (salt baths A61H33/04)
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/12: Antihypertensives
- A61H 2033/145: {with CO2}
- A61M 15/0065: {Inhalators with dosage or measuring devices (A61M15/0028 takes precedence; dosage devices incorporated in aerosol cans B65D83/52)}
- A61M 15/08: Inhaling devices inserted into the nose
- A61M 2202/0225: Carbon oxides, e.g. Carbon dioxide
- A61M 2202/064: Powder
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61H: PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY (electrotherapy, magnetotherapy, radiation therapy or ultrasound therapy A61N)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Apparatus and methods deliver physiologically active agents in the presence of adjuvant gases. The adjuvant gases can enhance the effectiveness of the drug, lower the dosage of drug or concentration of drug necessary to achieve a therapeutic result, or both. Exemplary adjuvant gases include carbon dioxide, nitric oxide, nitrous oxide, and dilute acid gases.

## Claims

### Claim 1

A method for delivering physiologically active agents to tissue, said method comprising:
contacting a tissue surface with a physiologically active agent; and
suffusing the tissue surface with an adjuvant gas which promotes uptake of the agent by the tissue or vascular circulation and/or which promotes an activity of the agent.

### Claim 2 (depends on 1)

A method as in claim 1, wherein at least a portion of the adjuvant gas is suffused simultaneously with contacting of at least a portion of the agent.

### Claim 3 (depends on 1)

A method as in claim 1, wherein at least a portion of the adjuvant gas is suffused prior to contacting the agent.

### Claim 4 (depends on 1)

A method as in claim 1, wherein at least a portion of the agent is suffused prior to contacting the adjuvant gas.

### Claim 5 (depends on 1, 2, 3, 4)

A method as in any one of claims 1 to 4, wherein contacting comprises placing a solid, powder, or liquid form of the agent on or over the tissue surface.

### Claim 6 (depends on 1, 2, 3, 4)

A method as in any one of claims 1 to 4, wherein contacting comprises suffusing the physiologically active agent in a gaseous, vapor, mist, or powder form.

### Claim 7 (depends on 1, 2, 3, 4)

A method as in any one of claims 1 to 4, wherein the adjuvant gas is selected from the group consisting of carbon dioxide, nitric oxide, nitrous oxide, and dilute acid gases.

### Claim 8 (depends on 1, 2, 3, 4)

A method as in any one of claims 1 to 4, wherein the physiologically active agent comprises at least one drug selected from the group consisting of nitroglycerin, triptans, imidazopyridines, 5-HT3 antagonists, epinephrine, angiotensin II, atrophine, apomorphine, and opioids.

### Claim 9 (depends on 1, 2, 3, 4)

A method as in any one of claims 1 to 4, wherein the tissue surface comprises a mucosal surface.

### Claim 10 (depends on 4)

A method as in claim 4, wherein the mucosal surface is a nasal surface, an oral surface, an ocular tissue surface, or an auricular tissue surface.

### Claim 11

A system for infusing a mucosal surface with a physiologically active substance, said system comprising:
a source of an adjuvant gas;
a source of the physiologically active substance in a fluid form; and
means for delivering both the adjuvant gas and the physiologically active substance to the mucosal surface.

### Claim 12 (depends on 11)

A system as in claim 11, wherein the delivering means comprises a hand-held dispenser.

### Claim 13 (depends on 12)

A system as in claim 12, wherein the hand-held dispenser comprises a receptacle of pressurized adjuvant gas and a valve assembly for releasing the gas at a controlled flow rate in the range from 0.5 cc/sec to 20 cc/sec.

### Claim 14 (depends on 13)

A system as in claim 13, wherein the physiologically active substance is dissolved or suspended in the pressurized adjuvant gas.

### Claim 15 (depends on 11)

A system as in claim 11, wherein the source of adjuvant gas comprises a first receptacle and the source of physiologically active substance comprises a second receptacle.

### Claim 16 (depends on 15)

A system as in claim 15, wherein the means for delivering both the adjuvant gas and the physiologically active substance comprises a common conduit and nozzle for delivering the gas and substance simultaneously.

### Claim 17 (depends on 11, 12, 13, 14, 15, 16)

A system as in any one of claims 11 to 16, wherein the source of adjuvant gas comprises a gas selected from the group consisting of carbon dioxide, nitric oxide, nitrous oxide, and dilute acid gases.

### Claim 18 (depends on 17)

A system as in claim 17, wherein the physiologically active agent comprises at least one drug selected from the group consisting of nitroglycerin, triptans, imidazopyridines, 5-HT3 antagonists, epinephrine, angiotensin II, atrophine, apomorphine, and opioids.
